𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of ionidamine in patients with metastatic breast cancer

✍ Scribed by H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tormey

Publisher
Springer US
Year
1990
Tongue
English
Weight
193 KB
Volume
8
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

πŸ“œ SIMILAR VOLUMES

Phase II study of flutamide in patients
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study
✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.